Shares of Clovis Oncology, Inc. (NASDAQ:CLVS) have received an average recommendation of “Hold” from the twenty-one brokerages that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $89.63.
A number of research analysts recently weighed in on CLVS shares. ValuEngine raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. BidaskClub raised shares of Clovis Oncology from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Clovis Oncology in a research report on Friday, November 3rd. Oppenheimer reaffirmed a “hold” rating on shares of Clovis Oncology in a research report on Tuesday, October 10th. Finally, Morgan Stanley lowered their price objective on shares of Clovis Oncology from $89.00 to $86.00 and set an “overweight” rating on the stock in a research report on Thursday, November 2nd.
Clovis Oncology (NASDAQ:CLVS) traded up $3.91 on Tuesday, hitting $60.67. 1,978,600 shares of the company were exchanged, compared to its average volume of 1,439,021. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. Clovis Oncology has a one year low of $45.42 and a one year high of $99.45. The company has a market capitalization of $3,050.00, a price-to-earnings ratio of -7.33 and a beta of 1.38.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of Clovis Oncology stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $64.16, for a total value of $192,480.00. Following the completion of the transaction, the insider now owns 182,583 shares in the company, valued at $11,714,525.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thorlef Spickschen sold 4,500 shares of Clovis Oncology stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $64.97, for a total transaction of $292,365.00. Following the completion of the transaction, the director now owns 21,118 shares of the company’s stock, valued at approximately $1,372,036.46. The disclosure for this sale can be found here. Insiders sold 18,000 shares of company stock valued at $1,123,425 in the last quarter. Corporate insiders own 12.50% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Phocas Financial Corp. purchased a new position in shares of Clovis Oncology in the second quarter worth about $112,000. Capital Analysts LLC purchased a new position in shares of Clovis Oncology in the third quarter worth about $111,000. Cypress Capital Management LLC WY increased its stake in shares of Clovis Oncology by 272.7% in the third quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 1,500 shares in the last quarter. Stevens Capital Management LP purchased a new position in shares of Clovis Oncology in the second quarter worth about $257,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of Clovis Oncology by 0.7% in the second quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 20 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “Clovis Oncology, Inc. (CLVS) Given Consensus Rating of “Hold” by Analysts” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/23/clovis-oncology-inc-clvs-given-consensus-rating-of-hold-by-analysts.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.